Moderna, Inc. (MRNA): Cash & Equivalents
$2.60B
As of 2025-12-31
$1.72B
As of 2026-06-30
-6.8%
3-year compound annual growth
-0.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.60B | +34.7% | 2026-02-20, Balance as of period end |
| 2024-12-31 | $1.93B | -33.7% | 2026-02-20, Balance as of period end |
| 2023-12-31 | $2.91B | -9.3% | 2026-02-20, Balance as of period end |
| 2022-12-31 | $3.21B | -53.2% | 2025-02-21, Balance as of period end |
| 2021-12-31 | $6.85B | +161.0% | 2024-02-23, Balance as of period end |
| 2020-12-31 | $2.62B | n/m | 2023-02-24, Balance as of period end |
| 2019-12-31 | $236.00M | -64.2% | 2022-02-25, Balance as of period end |
| 2018-12-31 | $658.36M | +388.2% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $134.86M | +169.3% | 2019-03-13, Balance as of period end |
| 2016-12-31 | $50.08M | n/a | 2019-03-13, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Moderna, Inc. (MRNA) | 2025-12-31 | $2.60B | +34.7% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $839.00M | +26.4% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $133.82M | +15.5% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Novavax Inc (NVAX) | 2025-12-31 | $240.63M | -54.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
Compare MRNA, QGEN, EXEL, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗